Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 in Advanced Breast Cancer and Solid Tumors
NCT05470348Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of izalontamab brengitecan in breast cancer and solid tumor, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Recommended Phase II Dose at 21 days and 1 more. Started Aug 2022; status: recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
breast cancersolid tumor
Beyond the preview
Go deeper on NCT05470348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470348.